Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

Summary

This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-101 clinical study (induction study) and who are willing to continue their treatment.

Timeline

Start

2018-01-20

Primary completion

2022-07-12

Completion

2022-08-15

Drugs

Indications